Search results
Results From The WOW.Com Content Network
In 2015, a phase I clinical trial of PAC-1 opened for enrollment of cancer patients, and in 2016, it was announced that PAC-1 had been granted Orphan Drug Designation for treatment of glioblastoma by the FDA, and in late 2017 a Phase 1b trial began of PAC-1 plus temozolomide for treatment of patients with recurrent glioblastoma or anaplastic ...
Pituitary gland tumors are very common in the canine. A productive form arising from the anterior pituitary is the primary cause of Cushing's disease of dogs. This tumor causes excessive production of cortisol from the adrenal cortex which leads to the classic signs of alopecia (hair loss), polyuria (excessive urination), polydipsia (excessive water drinking), and a pot-bellied appearance of ...
Lomustine was approved by the FDA to treat high-grade gliomas in 1976. Lomustine, alone or in combination with other chemotherapeutic drugs, was the standard of care following surgery and/or radiation up until the early twenty-first century. In the United States, lomustine is currently approved for recurrent high-grade gliomas. [23]
The DRKS is an open access, free of charge online register for clinical trials and is available both in English and German. DRKS is part of the WHO's ICTRP. The DRKS works with two partner registries in Germany, DeReG (German Registry for Somatic Gene-Transfer Trials) and Clinical Trial Registry of the University Medical Center Freiburg. [4]
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
A study of trials conducted between 2008 and 2012 found that about half of those required to be reported had not been. [18] [19] A 2014 study of pre-2009 trials found that many had serious discrepancies between what was reported on clinicaltrials.gov versus the peer-reviewed journal articles reporting the same studies.
Alternating electric field therapy is an FDA-approved therapy for newly diagnosed [92] and recurrent glioblastoma. [93] In 2015, initial results from a phase-III randomized clinical trial of alternating electric field therapy plus temozolomide in newly diagnosed glioblastoma reported a three-month improvement in progression-free survival, and a ...
TM-601 which is the synthetic version of chlorotoxin is under phase II clinical trial. Iodine-131-TM-601 is used to treat malignant glioma. TM-601 is also a candidate for targeting gliomas because it crosses blood-brain and tissue barriers and binds to malignant brain tumor cells without affecting healthy tissue. [9]